Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Terevalefim. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 8/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.41 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terevalefim SCHEMBL7169259 | 1.00 | ELANE (0.42) | ELANEMAPTKMT2ASMN1; SMN2MEN1 | |
| Terevalefim SCHEMBL7079437 | 0.86 | ELANE (0.33) | ELANEMAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL6348254 | 0.79 | ENPP3 (0.62) | ELANEMAPTKMT2ASMN1; SMN2ALDH1A1 | |
| Terevalefim SCHEMBL1225336 | 0.68 | KMT2A (0.49) | MAPTKMT2ASMN1; SMN2MEN1ALDH1A1 | |
| Terevalefim SCHEMBL1225335 | 0.68 | KMT2A (0.49) | MAPTKMT2ASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL12204829 | 0.65 | KDM4E (0.51) | ELANEMAPTSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL2399767 | 0.65 | F2 (0.48) | ELANEMAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL2399771 | 0.65 | F2 (0.48) | ELANEMAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL8511661 | 0.62 | KMT2A (0.60) | MAPTKMT2ASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL2336029 | 0.61 | MAPT (0.59) | MAPTKMT2ASMN1; SMN2MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355921-A2 | MODULATORS OF CELLULAR PROLIFERATION AND ANGIOGENESIS, METHODS FOR USE AND IDENTIFICATION THEREOF | North Shore-Long Island Jewish Health System (US) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002002593-A2 | MODULATORS OF CELLULAR PROLIFERATION AND ANGIOGENESIS, METHODS FOR USE AND IDENTIFICATION THEREOF | NORTH SHORE-LONG ISLAND JEWISH HEALTH SYSTEM (US) | 2002-01-10 | — | — | WO | disclosed |